Cargando…
Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo
Amyloid imaging represents a major advance in neuroscience, enabling the detection and quantification of pathologic protein aggregations in the brain. In this review we survey current amyloid imaging techniques, focusing on positron emission tomography (PET) with ^{11}carbon-labelled Pittsburgh Comp...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804478/ https://www.ncbi.nlm.nih.gov/pubmed/19847050 http://dx.doi.org/10.3233/BEN-2009-0232 |
_version_ | 1782176153524502528 |
---|---|
author | Rabinovici, G. D. Jagust, W. J. |
author_facet | Rabinovici, G. D. Jagust, W. J. |
author_sort | Rabinovici, G. D. |
collection | PubMed |
description | Amyloid imaging represents a major advance in neuroscience, enabling the detection and quantification of pathologic protein aggregations in the brain. In this review we survey current amyloid imaging techniques, focusing on positron emission tomography (PET) with ^{11}carbon-labelled Pittsburgh Compound-B ((11)C-PIB), the most extensively studied and best validated tracer. PIB binds specifically to fibrillar beta-amyloid (Aβ) deposits, and is a sensitive marker for Aβ pathology in cognitively normal older individuals and patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). PIB-PET provides us with a powerful tool to examine in vivo the relationship between amyloid deposition, clinical symptoms, and structural and functional brain changes in the continuum between normal aging and AD. Amyloid imaging studies support a model in which amyloid deposition is an early event on the path to dementia, beginning insidiously in cognitively normal individuals, and accompanied by subtle cognitive decline and functional and structural brain changes suggestive of incipient AD. As patients progress to dementia, clinical decline and neurodegeneration accelerate and proceed independently of amyloid accumulation. In the future, amyloid imaging is likely to supplement clinical evaluation in selecting patients for anti-amyloid therapies, while MRI and FDG-PET may be more appropriate markers of clinical progression. |
format | Text |
id | pubmed-2804478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-28044782010-01-11 Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo Rabinovici, G. D. Jagust, W. J. Behav Neurol Research Article Amyloid imaging represents a major advance in neuroscience, enabling the detection and quantification of pathologic protein aggregations in the brain. In this review we survey current amyloid imaging techniques, focusing on positron emission tomography (PET) with ^{11}carbon-labelled Pittsburgh Compound-B ((11)C-PIB), the most extensively studied and best validated tracer. PIB binds specifically to fibrillar beta-amyloid (Aβ) deposits, and is a sensitive marker for Aβ pathology in cognitively normal older individuals and patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). PIB-PET provides us with a powerful tool to examine in vivo the relationship between amyloid deposition, clinical symptoms, and structural and functional brain changes in the continuum between normal aging and AD. Amyloid imaging studies support a model in which amyloid deposition is an early event on the path to dementia, beginning insidiously in cognitively normal individuals, and accompanied by subtle cognitive decline and functional and structural brain changes suggestive of incipient AD. As patients progress to dementia, clinical decline and neurodegeneration accelerate and proceed independently of amyloid accumulation. In the future, amyloid imaging is likely to supplement clinical evaluation in selecting patients for anti-amyloid therapies, while MRI and FDG-PET may be more appropriate markers of clinical progression. IOS Press 2009 2009-10-21 /pmc/articles/PMC2804478/ /pubmed/19847050 http://dx.doi.org/10.3233/BEN-2009-0232 Text en Copyright © 2009 Hindawi Publishing Corporation and the authors. http://creativecommons.org/licenses/by/3.0 This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Rabinovici, G. D. Jagust, W. J. Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo |
title | Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo |
title_full | Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo |
title_fullStr | Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo |
title_full_unstemmed | Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo |
title_short | Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo |
title_sort | amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804478/ https://www.ncbi.nlm.nih.gov/pubmed/19847050 http://dx.doi.org/10.3233/BEN-2009-0232 |
work_keys_str_mv | AT rabinovicigd amyloidimaginginaginganddementiatestingtheamyloidhypothesisinvivo AT jagustwj amyloidimaginginaginganddementiatestingtheamyloidhypothesisinvivo |